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Background: Adherence to long-term chelation therapy in transfusion-dependent patients is critical to prevent iron
overload-related complications. Once-daily deferasirox dispersible tablets (DT) have proven long-term efficacy and
safety in patients ≥2 years old with chronic transfusional iron overload. However, barriers to optimal adherence
remain, including palatability, preparation time, and requirements for fasting state. A new film-coated tablet (FCT)
formulation was developed, swallowed once daily (whole/crushed) with/without a light meal.
Methods: The open-label, Phase II ECLIPSE study evaluated patient-reported outcomes (PROs) in transfusion-
dependent thalassemia or lower-risk myelodysplastic syndromes patients randomized 1:1 to receive deferasirox DT
or FCT over 24 weeks as a secondary outcome of the study. Three PRO questionnaires were developed to evaluate
both deferasirox formulations: 1) Modified Satisfaction with Iron Chelation Therapy Questionnaire; 2) Palatability
Questionnaire; 3) Gastrointestinal (GI) Symptom Diary.
Results: One hundred seventy three patients were enrolled; 87 received the FCT and 86 the DT formulation. FCT
recipients consistently reported better adherence (easier to take medication, less bothered by time to prepare medication
and waiting time before eating), greater satisfaction/preference (general satisfaction and with administration of medicine),
and fewer concerns (less worry about not swallowing enough medication, fewer limitations in daily activities, less concern
about side effects). FCT recipients reported no taste or aftertaste and could swallow all their medicine with an acceptable
amount of liquid. GI summary scores were low for both formulations.
Conclusions: These findings suggest a preference in favor of the deferasirox FCT formulation regardless of underlying
disease or age group. Better patient satisfaction and adherence to chelation therapy may reduce iron overload-
related complications.
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In patients with hematological disorders requiring red
blood cell transfusions to treat anemia, such as those
with transfusion-dependent thalassemia (TDT) and mye-
lodysplastic syndromes (MDS), long-term iron chelation
therapy is necessary to remove excess iron and prevent
organ failure [1]. Because iron overload is a chronic con-
dition and the benefits of chelation therapy are not im-
mediately perceivable, compliance with chelation
therapy has a positive influence on the occurrence of
iron overload-related complications and survival [2–4].
As such, a convenient and well-tolerated chelation regi-
men is required for optimal patient outcomes.
The once-daily oral deferasirox dispersible tablet (DT)
formulation (Exjade®) has been used in clinical practice
for over a decade, with a well-established efficacy and
safety profile in patients ≥2 years of age with chronic
transfusional iron overload [5–13]. Oral deferasirox DT
offered an improvement over parenteral deferoxamine
(DFO, Desferal®), particularly in terms of compliance,
convenience, patient satisfaction, and health-related
quality of life [2, 14–16]. However, barriers still exist to
optimal adherence with deferasirox DT, including the
need to take the drug in a fasting state, requirements for
careful dispersion prior to ingestion, the chalky
consistency, and suboptimal gastrointestinal (GI) toler-
ability [17]. In recognition of the importance of patient
adherence to chelation therapy, a film-coated tablet
(FCT) formulation for oral administration (either whole
or crushed and mixed with soft foods) was developed as
an alternative treatment option intended to improve pa-
tient acceptability and therefore compliance. Both FCT
and DT contain the same active substance (deferasirox)
and are administered once daily. Dose is adjusted ac-
cording to body weight and response to treatment [18–
20]. In contrast to the DT, the FCT does not contain the
excipients lactose and sodium lauryl sulphate and can be
taken with or without a light meal [19, 20] offering a
more simple and convenient mode of administration
with potential improvements in GI tolerability.
The Phase II, randomized open-label ECLIPSE study
demonstrated similar safety profiles for the FCT and DT,
including acceptable GI tolerability for both formulations
[20]. The study provided evidence that patients receiving
the FCT remained on treatment for longer and were more
compliant than those receiving the DT. The patient-
reported outcome (PRO) analyses also indicated a benefit
in favor of the deferasirox FCT, including greater adher-
ence, greater satisfaction, fewer concerns and better palat-
ability [20]. Furthermore, a post-marketing assessment of
safety outcomes from data available in the USA (where
the FCT became available in April 2015), demonstrated a
tendency towards better tolerability with the FCT, particu-
larly in the GI tract [21].Here, we report analyses from the individual response
categories of the various PRO instruments used for the
ECLIPSE study, specifically the modified Satisfaction
with Iron Chelation Therapy (mSICT) and Palatability
Questionnaire items, as well as the GI Symptom Diary.
These analyses were performed to better understand the
drivers of the improved PROs observed in patients re-
ceiving the FCT versus those receiving DT.Methods
Patients
Key inclusion and exclusion criteria have been described
elsewhere [20]. In summary, iron overloaded and previ-
ously chelated or chelation-naïve male and female patients
(aged ≥10 years) with TDT or revised International Prog-
nostic Scoring System very-low, low- or intermediate-risk
MDS were enrolled. Key exclusion criteria were: creatinine
clearance below contraindication limit as per local label
(< 60 mL/min or < 40 mL/min); serum creatinine > 1·5 ×
upper limit of normal (ULN); alanine aminotransferase
> 5 ×ULN (unless liver iron concentration confirmed as
> 10 mg Fe/g dry weight ≤ 6 months prior to screening);
urine protein/urine creatinine ratio > 0·5 mg/mg; or
impaired GI function.Study design
ECLIPSE was a 24-week, open-label, randomized, mul-
ticenter, two-arm, Phase II study that evaluated the
deferasirox FCT and DT formulations as previously
described [20]. Randomization was stratified by under-
lying disease and prior chelation treatment. As per
protocol, deferasirox DT (taken on an empty stomach,
at least 30 min before the next meal) was to be initiated
at 20 mg/kg/day in chelation-naïve patients; pre-
treated patients were to be initiated at a dose equiva-
lent to their prior chelation treatment (taking conver-
sion rules into account, e.g., 20 mg/kg/day deferasirox
equivalent to ~ 40 mg/kg/day DFO) following a 5-day
washout period. As per protocol, deferasirox FCT
(taken with or after a light meal) was to be initiated at
14 mg/kg/day in chelation-naïve patients; pre-treated
patients were to be initiated at a dose equivalent to
their prior chelation treatment (taking conversion rules
into account, e.g., 20 mg/kg/day DT equivalent to
14 mg/kg/day FCT; conversion factor 1·43) following a
5-day washout period. Dose adjustments to improve
treatment response based on serum ferritin levels and
the investigator’s judgement were recommended every
4 weeks for chelation-naïve patients, and every
3 months for pre-treated patients, in increments of 5–
10 mg/kg/day for DT or 3·5–7 mg/kg/day for FCT, up
to a maximum dose of 40 mg/kg/day for DT and
28 mg/kg/day for FCT.
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Clinical Practice guidelines and the Declaration of
Helsinki and was approved by independent ethics com-
mittees at participating sites. Patients (or parents/guard-
ians) provided written, informed consent prior to
enrollment.
PRO instruments
Evaluation of both deferasirox formulations on patient sat-
isfaction, palatability, and GI symptoms was conducted as
a secondary endpoint of the study using PRO question-
naires. Three PRO questionnaires were developed: 1)
mSICT; 2) Palatability Questionnaire; and 3) GI Symp-
toms Diary. Patients completed all PRO questions via a
hand-held electronic device either at home (daily diaries)
or during scheduled site visits. The instruments under-
went full qualitative evaluation [22]; linguistic and psycho-
metric evaluation of the PRO questionnaires was
conducted during the trial, supporting the reliability and
construct-related validity of the scores [23].
The mSICT questionnaire used five-point response
scales to assess adherence (six questions), satisfaction/
preference (two questions), and concern domains (three
questions). Domain scores were calculated by summing
the scores from all questions within the domain; higher
scores in adherence (range 6–30) and satisfaction/prefer-
ence (range 2–10) domains indicated worse outcomes,
higher scores in concern domain (range 3–15) indicated
fewer concerns. The Palatability Questionnaire consisted
of four items: taste and aftertaste of the medication
(5-point response scale: 1 = very good to 5 = very bad),
whether the medication was taken (i.e., whether the
patient vomited after swallowing medication or not) and
how the patient perceived the amount of medication to be
taken (not enough, just enough, or too much). Overall
palatability score ranged from 0 (worst) to 11 (best). These
two questionnaires were completed at the start of treat-
ment [SOT], which was week 2 after the first dose (or
week 3 if missing), week 3, 13, and end of treatment
(within 7 days of the last dose).
The GI Symptom Diary, completed daily, consisted of
six items; five items (pain in your belly, nausea, vomit-
ing, constipation, diarrhea) rated on an 11-point scale (0
= best, 10 = worst) and the sixth item, bowel movement
frequency during the past 24 h, using seven response
options 0 = 0 (none), 1 = 1, 2 = 2, 3 = 3, 4 = 4, 5 = 5–10 and
6 = ≥ 11. The overall GI summary score was calculated from
the responses to the five items that used the 11-point scale,
ranging from 0 to 50, with higher scores indicating worse
symptoms. Item six was analysed as a standalone item.
Summary scores for each of the three PRO question-
naires were also summarized by underlying anemia
(thalassemia or MDS), and age categories (10 to < 13, 13
to < 18, 18 to < 50, 50 to < 65 and ≥ 65 years).Statistical evaluations
Standard descriptive analyses were performed. No hy-
pothesis was tested. The minimally important difference
(MID) was calculated (utilizing ½ standard deviation
[SD] [24] and standard error of measurement [25]) for
overall scores for the mSICT and palatability summary
score, representing the smallest difference between the
two treatment groups that is considered clinically im-
portant or that implies treatment benefit [26]. MID
scores > 1 point for the mSICT domains and palatability
scores and MID scores of 0·24 to 0·39 for the GI symp-
tom score indicate a meaningful difference between
groups. The full analysis set (FAS) includes all patients
randomized to receive treatment, N. The term ‘evaluable
patients’ refers to those patients who provided a re-
sponse to the PRO instruments, as indicated by the in-
vestigator. A supportive analysis was conducted to assess
the robustness of the PRO results. Missing PRO scores
(from mSICT, palatability and GI PRO questionnaire)
were imputed using a multiple imputation method
under missing at random assumption (MAR, i.e. the
probability of missing data is unrelated to the values of
PRO score). Given that the missing data patterns ob-
served in the three PRO measures were monotone and
intermittent (Table 1), an assessment based on the rea-
sons for missing PRO measures was done, which sup-
ported MAR as an acceptable assumption to assess the
robustness of the main analysis of PRO measures col-
lected during the trial.
Results
Patient disposition and PRO instrument response
In total, 173 patients from 16 countries worldwide were
randomized 1:1 to receive deferasirox DT (N = 86) or
FCT (N = 87) treatment. Overall, 73 (84·9%) and 77
(88·5%) patients in the DT and FCT arm, respectively,
completed the treatment period. The treatment groups
were balanced with respect to type of anemia and prior
chelation therapy, with 70 TDT patients in each arm
and 77 and 79 previously chelated patients in the DT
and FCT arm, respectively.
A similar proportion of patients completed the three
questionnaires for both formulations at the SOT and at
the end of treatment (EOT), with the response rate gen-
erally lower at the end of the study (Table 1). PRO
results obtained using imputed scores, to account for
missing PROs, were similar to the main PRO analyses
(Fig. 1).
mSICT and Palatability Questionnaire mean domain results
Completion of these two PRO questionnaires declined
from ~ 80% at SOT to 70% at EOT in both treatment
arms (Table 1). As previously reported, patients receiv-
ing the FCT consistently reported greater adherence,
Table 1 Completion of the three PRO instruments at each assessment during the study



















−2 60 (69.8) 59 (67.8)
−1 62 (72.1) 52 (59.8)
1 70 (81.4) 69 (79.3)
2 70 (81.4) 70 (80.5) 69 (80.2) 70 (80.5) 65 (75.6) 71 (81.6)
3 58 (67.4) 51 (58.6) 57 (66.3) 51 (58.6) 64 (74.4) 66 (75.9)
4 60 (69.8) 64 (73.6)
5 58 (67.4) 64 (73.6)
6 64 (74.4) 57 (65.5)
7 57 (66.3) 53 (60.9)
8 59 (68.6) 51 (58.6)
9 55 (64.0) 49 (56.3)
10 53 (61.6) 49 (56.3)
11 51 (59.3) 44 (50.6)
12 51 (59.3) 45 (51.7)
13 59 (68.6) 64 (73.6) 59 (68.6) 62 (71.3) 49 (57.0) 50 (57.5)
14 51 (59.3) 44 (50.6)
15 49 (57.0) 43 (49.4)
16 48 (55.8) 41 (47.1)
17 44 (51.2) 40 (46.0)
18 44 (51.2) 38 (43.7)
19 40 (46.5) 37 (42.5)
20 40 (46.5) 39 (44.8)
21 39 (45.3) 37 (42.5)
22 38 (44.2) 35 (40.2)
23 36 (41.9) 34 (39.1)
24 63 (73.3) 60 (69.0) 63 (73.3) 60 (69.0) 32 (37.2) 26 (29.9)
SOT for the mSICT and palatability were defined as the first PRO assessment at week 2 (or week 3 if missing); for the GI Symptom Diary, week 1 was taken as SOT;
*includes patients with at least four complete daily responses. DT Dispersible tablet, FCT Film-coated tablet, GI Gastrointestinal, PRO Patient-reported outcome,
mSICT modified Satisfaction with iron chelation therapy, SOT Start of treatment
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receiving the DT. The difference in scores between treat-
ment groups was > 1 point (MID = 1) at almost all visits
for all three domains, indicating a clinically meaningful
difference (Fig. 1a, b and c) [20]. Mean palatability sum-
mary scores in the FCT treatment arm were consistently
high (~ 11) compared with the DT arm (~ 8–9) (Fig. 1d)
[20]. The difference in scores between treatment groups
was > 1 point (MID = 1), indicating a clinically meaning-
ful difference. In all mean domain scores for the two
questionnaires, the 95% confidence intervals did not
overlap at most time points analysed. Analysis of sum-
mary scores by underlying anemia or age group did not
reveal any notable differences compared to the overall
findings (see Additional file 1: Table S2).Item results from the mSICT adherence domain
To better understand the improved mSICT and Palat-
ability Questionnaire mean domain results with FCT
versus DT, patient responses to individual questionnaire
items were evaluated. The adherence domain consisted
of six questions related to: trouble remembering to take
the medication, thinking about stopping the medication,
following their doctor’s instructions (including reasons
for not always taking the medication, if a patient indi-
cated they did not ‘always’ take their medication as
instructed), how hard/easy it was to take the medication,
how bothered they were about the time to prepare the
medication and the time to wait to eat food. Overall,
patients in the FCT arm reported consistent mean ad-

























































   
   
   
   




   
   
   
   












a  Adherence domain score


















d  Palatability summary score
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Fig. 1 Mean ± 95% CI domain scores for patient-reported outcomes (adherence, satisfaction/preference, and concern) (a–c), mean palatability score
(d), and mean gastrointestinal symptom scores (e). For adherence (a; scale 6–30), satisfaction/preference (c; scale 2–10), and GI symptoms (e; scale
0–50), higher scores indicate worse outcomes/symptoms. For concern (c; scale 3–15) and palatability (d; scale 0–11), higher scores indicate fewer
concerns and better palatability. a–d, SOT was defined as week 2 assessment. If missing, then the week 3 assessment was considered SOT. e, SOT was
defined as week 1 score. If missing, then the week 2 score was considered SOT. CI, confidence interval; DFX, deferasirox; DT, dispersible tablet; EOT,
end of treatment; FCT, film-coated tablet; SOT, start of treatment. Figure adapted from Taher AT et al. Am J Hematology 2017;92(5):420–428. Published
with kind permission of John Wiley & Sons ©2017 The Authors, American Journal of Hematology, Published by Wiley Periodicals, Inc.
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compared to SOT (10·3; Fig. 1a) and were slightly higher
(indicating worse outcomes).
Most patients in both treatment arms reported ‘never
thinking about stopping medication’ at SOT. By EOT, theproportion of DT recipients who reported ‘never thinking
about stopping medication’ was 44·2% (n = 38/86 [n = 38/
63, 60·3% evaluable patients]) compared with 60·9% (n =
53/87 [n = 53/60, 88·3% evaluable patients]) of FCT recipi-
ents (Fig. 2a). The majority of FCT recipients (n = 65/87,
Taher et al. Health and Quality of Life Outcomes          (2018) 16:216 Page 6 of 1274·7% at SOT [n = 65/70, 92·9% evaluable patients]; n =
55/87, 63·2% at EOT [n = 55/60, 91·7% evaluable patients])
found it ‘very easy or easy’ to take their medication, in
comparison to DT recipients (n = 45/86, 52·3% at
SOT [n = 45/70, 64·3% evaluable patients]; n = 29/86,
33·7% at EOT [n = 29/63, 46·0% evaluable patients];
Fig. 2b). More patients in the FCT group were ‘not
bothered at all’ about the time it took to prepare
medication (Fig. 2c) or by the time they had to wait
to eat (Fig. 2d) than patients in the DT group at both
SOT and EOT.
A similar proportion of patients in both treatment
arms reported to ‘always’ follow their doctor’s instruc-
tions (Fig. 2e), both at SOT (FCT: n = 56/87, 64·4% [n
= 56/70, 80·0% evaluable patients] and DT: n = 58/86,
67·4% [n = 58/70, 82·9% evaluable patients]) and EOT
(FCT: n = 50/87, 57·5% [n = 50/60, 83·3% evaluable
patients] and DT: n = 48/86, 55·8% [n = 48/63, 76·2%
evaluable patients]). In both treatment arms, the pro-
portion of patients ‘rarely or never’ having trouble
remembering to take medication was similar (Fig. 2f ) at
SOT (FCT: n = 61/87, 70·1% [n = 61/70, 87·1% evaluable
patients] and DT: n = 61/86, 70·9% [n = 61/70, 87·1%
evaluable patients]), declining by EOT in the DT arm
(FCT: n = 53/87, 60·9% [n = 53/60, 88·3% evaluable
patients] and DT: n = 46/86, 53·5% [n = 46/63, 73·0%
evaluable patients]).Item results from the mSICT satisfaction domain
The satisfaction domain consisted of three questions
related to: satisfaction with how they took the medica-
tion, how satisfied/dissatisfied they were with the medi-
cation in general, and which type of medication did they
like the best (see Overall Preference). Overall, patients in
the FCT arm reported consistent mean satisfaction
scores from SOT (2·8) to EOT (2·9), whereas overall
scores in the DT arm worsened at EOT (5·8) compared
to SOT (5·2, Fig. 1b) and were generally higher (indicat-
ing worse outcome).
More patients in the FCT than the DT group were
‘very satisfied’ or ‘satisfied’ with taking their medication
at SOT (FCT: n = 67/87, 77·0% [n = 67/70, 95·7% evalu-
able patients] and DT: n = 32/86, 37·2% [n = 32/70,
45·7% evaluable patients]) and EOT (FCT: n = 54/87,
62·1% [n = 54/60, 90·0% evaluable patients] and DT: n =
26/86, 30·2% [n = 26/63, 41·3% evaluable patients]). More
FCT than DT recipients were also ‘very satisfied’ or ‘sat-
isfied’ with their medication overall at SOT (FCT: n =
67/87, 77·0% [n = 67/70, 95·7% evaluable patients] and
DT: n = 40/86, 46·5% [n = 40/70, 57·1% evaluable pa-
tients]) and EOT (FCT: n = 56/87, 64·4% [n = 56/60, 93·3%
evaluable patients] and DT: n = 28/86, 32·6% [n = 28/63,
44·4% evaluable patients]).Item results from the mSICT concerns domain
The concerns domain consisted of three questions re-
lated to: worries about not swallowing enough medica-
tion, medication limiting usual activities, and feeling
upset about side effects of medication. Overall, patients
in the FCT arm reported consistent mean concern
scores from SOT (13·8) to EOT (13·7), whereas overall
scores in the DT arm worsened at EOT (11·8) compared
to SOT (12·9, Fig. 1c) and were generally lower (indicat-
ing more concerns). For all questions, there were min-
imal concerns for both medications at SOT and EOT
(Fig. 3a, b and c). There was a general trend for more
patients in the FCT than the DT group reporting ‘never’
or ‘rarely’ feeling concerned at SOT and EOT.
Item results from the Palatability Questionnaire
The Palatability Questionnaire consisted of four ques-
tions to assess taste, aftertaste, whether the medication
was taken (e.g., swallowed or vomited), and how the pa-
tient perceived the amount of medication (liquid) to be
taken. Overall, patients in the FCT arm reported consist-
ently high mean palatability scores from SOT (10·8) to
EOT (10·9), where a score of 11 was equivalent to the
best outcome, whereas overall scores in the DT arm
were lower (9·0 at SOT and 8·8 at EOT) and more vari-
able at each time point (Fig. 1d).
Most patients in both the FCT and DT arms swallowed
all their medication at SOT (FCT: n = 68/87, 78·2% [n =
68/70, 97·1% evaluable patients] and DT: n = 68/86,
79·1% [n = 68/69, 98·6% evaluable patients]) and EOT
(FCT: n = 60/87, 69·0% [n = 60/60, 100·0% evaluable
patients] and DT: n = 59/86, 68·6% [n = 59/63, 93·7%
evaluable patients]; Fig. 4a). No patient vomited within
30 min of swallowing their medication. The majority of
FCT and DT recipients confirmed that the amount of
liquid they took with their medicine for iron overload on
that given day was ‘just enough’ both at SOT (FCT: n =
63/87, 72·4% [n = 63/70, 90·0% evaluable patients] and
DT: n = 53/86, 61·6% [n = 53/69, 76·8% evaluable
patients]) and EOT (FCT: n = 52/87, 59·8% [n = 52/60,
86·7% evaluable patients] and DT: n = 49/86, 57·0% [n =
49/63, 77·8% evaluable patients]); however, more DT
than FCT recipients reported that it was ‘too much’
(SOT: n = 15/86, 17·4% [n = 15/69, 21·7% evaluable
patients] versus n = 5/87, 5·8% [n = 5/70, 7·1% evaluable
patients]; EOT: n = 12/86, 14·0% [n = 12/63, 19·0% evalu-
able patients] versus n = 5/87, 5·8% [n = 5/60, 8·3% evalu-
able patients]; Fig. 4b). Nearly all patients in the FCT
group reported no issue with the taste (100% at SOT
and EOT) or aftertaste (98% at SOT and 100% EOT) of
their medicine; whereas ~ 20% of patients (~ 30% evalu-
able patients) at SOT and EOT in the DT group reported
that their medication had a ‘bad’ or ‘very bad’ taste or
aftertaste (Fig. 4c and d).
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Fig. 2 Response frequencies at week 2 (start of treatment) and end of treatment by treatment arm from the mSICT adherence domains, a
Thinking about stopping medication, b How hard/easy to take the medication, c Time to prepare medication, d Waiting time to eat, e Following
doctor’s instructions, and f Trouble remembering to take medication. Numbers indicate the number of patients in each response category; *n < 5
patients. DT, dispersible tablet; FCT, film-coated tablet; mSICT, modified Satisfaction with Iron Chelation Therapy
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Fig. 3 Response frequencies at week 2 (start of treatment) and end of treatment by treatment arm from the mSICT concerns domains, a Swallowing
enough medication, b Medication limiting usual activities, c Feeling upset about side effects. Numbers indicate the number of patients in each
response category; *n < 5 patients. DT, dispersible tablet; FCT, film-coated tablet; mSICT, modified Satisfaction with Iron Chelation Therapy
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Evaluation of the preferred formulation of deferasirox
was assessed as part of the mSICT satisfaction domain.
In patients who received either the DT or the FCT, there
was a preference for the FCT (Fig. 5). At EOT, of
patients in the FCT arm, 53/87 (60·9% [n = 53/60, 88·3%
evaluable patients]) reported preference for the FCT,
while 3/87 (3·5% [n = 3/60, 5·0% evaluable patients]) pre-
ferred a DT. Of patients in the DT arm, 41/86 (47·7%
[n = 41/63, 65·1% evaluable patients]) reported prefer-
ence for a FCT, while 16/86 (18·6% [n = 16/63, 25·4%
evaluable patients]) preferred the DT.
GI Symptom Diary
Completion of the GI Symptom Diary also decreased over
the course of the study (Table 1). As previously reported
[20], the overall GI symptom scores were low for bothformulations over the course of the study (less than 3 out
of a maximum of 50; Fig. 1e), indicating that patients expe-
rienced very little concern associated with GI symptoms.
Analysis of summary scores by underlying anemia or age
group also did not reveal any notable differences compared
to the overall findings (see Additional file 1: Table S2).
Discussion
It has been well documented that adherence to iron
chelation therapy influences overall survival [2, 4, 27]. Al-
though the introduction of once-daily oral chelation with
deferasirox DT was an improvement over parenteral
DFO, the properties of deferasirox DT were still not ideal.
The deferasirox FCT formulation was specifically devel-
oped with the intention of improving patient acceptability,
to enhance patient satisfaction and therefore adherence to
iron chelation therapy. Besides evaluating the safety profile
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Fig. 4 Response frequencies at week 2 (start of treatment) and end of treatment by treatment arm from the Palatability Questionnaire items, a
Whether medication was taken, b Perceived amount of liquid, c Taste, and d Aftertaste. Numbers indicate the number of patients in each
response category; *n < 5 patients; DT, dispersible tablet; FCT, film-coated tablet
Taher et al. Health and Quality of Life Outcomes          (2018) 16:216 Page 9 of 12and pharmacokinetics of the deferasirox FCT relative to
the DT formulation, the ECLIPSE trial also examined de-
tailed PRO data to better understand patient preference
for, and satisfaction with, the FCT versus the DT. In gen-
eral, the PROs demonstrated that patients receiving either
the FCT or DT had no major issues regarding adherence,
preference, satisfaction, palatability, and GI tolerability
with their medication, with patients providing mostly neu-
tral or positive responses to the questionnaires. However,
patients receiving FCT and DT showed a clear patient
preference for the deferasirox FCT over the DT formula-
tion. Furthermore, these findings were maintained irre-
spective of underlying anemia or age group, indicating
consistent outcomes across patient subgroups. As previ-
ously reported, the mean domain scores from the mSICT
and Palatability Questionnaires showed adherence,
preference, satisfaction, and palatability in favor of thedeferasirox FCT [20]. Furthermore, the difference in
scores between treatment groups was of a magnitude that
implies a corresponding treatment benefit (the difference
being > 1 point [MID = 1]), indicating a clinically mean-
ingful difference. However, the GI symptom score diaries
revealed no clear differences between the two deferasirox
formulations, with the majority of patients showing GI
disturbances of minimal concern over the 24-week study.
This may be attributed to the majority of patients enrolled
having experienced prior chelation therapy and having
underlying thalassemia, in whom GI disturbances are usu-
ally mild-to-moderate [28]. Nevertheless, the analyses pre-
sented here show that item results from the mSICT and
Palatability Questionnaires provide several specific under-
lying factors that can be considered as reasons for patients
preferring the deferasirox FCT to a degree that may im-
prove their clinical outcomes.
Preferred formulation of deferasirox
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Fig. 5 Response frequencies for the preferred formulation of deferasirox at week 2 (start of treatment) and end of treatment by treatment arm.
Numbers indicate the number of patients in each response category; *n < 5 patients; DT, dispersible tablet; FCT, film-coated tablet
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showed that all FCT and DT patients generally followed
their doctor’s instructions when taking their medication,
had minimal trouble remembering to take their medica-
tion, and rarely thought about stopping. However, by
EOT a slightly lower proportion of patients in the DT
arm reported ‘never or rarely’ having trouble remember-
ing to take their medication compared to the FCT arm,
as well as ‘never’ thinking about stopping. The finding
that the majority of patients receiving the FCT formation
found it ‘easy’ or ‘very easy’ to take their medication
compared with those in the DT arm, along with not be-
ing bothered by the time it took to take their medication
or waiting to eat, suggests that the FCT may provide a
more convenient mode of administration. The FCT can
be taken either on an empty stomach or with a low-fat
meal (< 7% fat content and ~ 250 cal) [19], whereas it is
recommended that the DT is taken only on an empty
stomach at least 30 min before the next meal, following
dispersion in a glass of water, orange juice or apple juice
[18], which takes approximately 3 min to prepare. Previ-
ous studies have indicated that the ability to take defera-
sirox with food, at breakfast in particular, is important to
patients [17]. The mode and convenience of administra-
tion of the FCT also may have contributed to the major-
ity of patients feeling satisfied with their medication and
experiencing fewer concerns, such as worry over swal-
lowing enough medication or impact on their usual
activities. Further study is warranted to corroborate
these findings.
Patient responses to items on the Palatability Ques-
tionnaire revealed similar trends as those observed forthe mSICT items, whereby patients receiving the FCT
trended towards reporting more positive response. Some
patients receiving the DT reported that it tasted ‘bad’ or
‘very bad.’ However minimal issues with taste or after-
taste were reported by patients receiving the FCT. The
majority of FCT and DT recipients also confirmed that
the amount of liquid they took with their medicine was
‘just enough’. On the other hand, more DT recipients
compared to FCT recipients indicated that the amount
of liquid was ‘too much’, because of the need to disperse
their medication in ~ 200 mL (for doses ≥1 g, ~ 100 mL
for doses < 1 g). Taking all these factors into account,
adherence, satisfaction, concerns, and palatability, there
was a clear preference for the FCT over the DT both at
week 2 (SOT) and EOT.
This study was limited by the short duration of follow-
up – 24 weeks is a relatively short period of time in pa-
tients receiving chronic treatment for iron overload that
can last a lifetime – however, apparent differences were
notable between the two formulations both at 2 weeks
(SOT) and at EOT. In addition, not all patients com-
pleted the various PRO instruments (attributed to
missed patient visits, patients forgetting to bring their
PRO devices or oversight in completing the question-
naires during site visits), which may have led to some
bias in the findings. However, the completion rate was
similar for both formulations and as expected in a PRO
study, with a decline in response rate over the course of
the study, particularly for the GI questionnaire. This
may have been the result of the requirement for daily
completion during the study, which some patients may
have found burdensome. It should also be noted that the
Taher et al. Health and Quality of Life Outcomes          (2018) 16:216 Page 11 of 12completion rates were based on the FAS and were not
adjusted to account for decreasing numbers of patients
(discontinuations) over the 24-week study. Furthermore,
this was a descriptive, exploratory study. Additional
long-term experiences from patients in clinical practice
treated with the FCT, as well as other clinical trials with
longer treatment duration, are required to confirm
whether the improved satisfaction, preference, and ad-
herence shown for FCT are maintained over longer time
periods. With a short-term safety profile consistent with
the known deferasirox DT [20] – well characterized in
an extensive clinical trial program – longer follow-up of
patients receiving the FCT will also help determine
whether the improvements in PROs will translate into
better clinical outcomes. In particular, patients switching
from the DT to the FCT will require careful monitoring
to avoid potential ‘over-chelation’ with improved adher-
ence, even with the initial FCT dose reduction (e.g.,
20 mg/kg/day DT equivalent to 14 mg/kg/day FCT; con-
version factor 1·43).Conclusions
In conclusion, for all patients regardless of age group or
underlying disease, these findings from the detailed ana-
lyses of responses to various validated PRO instruments
could suggest a preference in favor of the once-daily defer-
asirox FCT formulation. The FCT, which contains the
same active ingredient as the DT but with excipients re-
moved, and can be taken orally once daily with or without
a light meal, may therefore be less burdensome to patients
than the DT formulation. Together with a safety profile
consistent with the known deferasirox DT formulation, as
previously reported [20], the deferasirox FCT may im-
prove patient experience with iron chelation therapy
resulting in greater adherence. It is anticipated that better
adherence will translate into a reduction in the frequency
and severity of iron overload-related complications.Additional file
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